Predicting serious liver scarring in hepatitis B patients

This study looks at whether non-invasive tests can tell if liver damage is reversing in people with hepatitis B who have been on antiviral therapy for at least a year. It aims to help avoid repeated liver biopsies.

This study is for people with NASH and moderate-to-advanced liver scarring (fibrosis). Researchers want to see if they can better measure how the scarring changes over time using a liver biopsy.

This study looks at whether certain blood markers—including inflammation and fat levels—can help predict scarring in fatty livers. Understanding this connection may help doctors better identify patients at risk for serious liver damage.

This study looks at what factors predict liver inflammation, scarring (fibrosis), and health outcomes in people with long-term hepatitis B or fatty liver disease. The goal is to better understand who is more likely to worsen over time.

This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.

This trial looks for better ways to detect liver scarring (fibrosis) in people with long-term liver disease. It may help find problems earlier.